SCLX (Scilex Holding Co) Capex-to-Revenue : 0.01 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Scilex Holding Co's Capital Expenditure for the three months ended in Sep. 2024 was $-0.15 Mil. Its Revenue for the three months ended in Sep. 2024 was $14.44 Mil.

Hence, Scilex Holding Co's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.01.

Scilex Holding Co Capex-to-Revenue Historical Data

The historical data trend for Scilex Holding Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co Capex-to-Revenue Chart

Scilex Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

0.03

0.05

0.01

Scilex Holding Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Capex-to-Revenue	Get a 7-Day Free Trial									-	-	0.01	0.01	0.01

Competitive Comparison of Scilex Holding Co's Capex-to-Revenue

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Capex-to-Revenue falls into.

Save Embed

;

Save Embed

;

Scilex Holding Co Capex-to-Revenue Calculation

Scilex Holding Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.33)	/	46.743
	=	0.01

Scilex Holding Co's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.15)	/	14.436
	=	0.01

Scilex Holding Co (NAS:SCLX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Scilex Holding Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Executives

Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632
Chris Ho	director, 10 percent owner, officer: Chief Financial Officer	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632